Guided Therapeutics, Inc.
GTHP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.00 Million |
|---|---|
| Enterprise Value | $16.96 Million |
| Earnings per Share | $-0.04 |
| Beta | 0.7 |
| Outstanding Shares | 96,536,000 |
Return
| Return on Equity | 64.64% |
|---|---|
| Return on Assets | -311.72% |
| Return on Invested Capital | 53.20% |
Valuation & Multiples
| P/E Ratio | -3.63 |
|---|---|
| PEG | 14.2 |
| Price to Sales | - |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 26.09 |
| Enterprise Value to EBIT | -6.41 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | -0.52 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Guided Therapeutics, Inc.
3 employees
CEO: Mark L. Faupel
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. T...